



# COLORADO

Department of Health Care  
Policy & Financing

## MINUTES OF THE MEETING OF THE COLORADO MEDICAID P&T COMMITTEE

Department of Health Care Policy and Financing  
Virtual Meeting via Zoom

April 13<sup>th</sup>, 2021

### 1. Call to Order

A quorum being present, J. FEINSTEIN officially called the meeting to order at 13:03 MT.

### 2. Roll Call

Board introductions were made. There were sufficient members for a quorum with eleven members participating.

#### A. Members Present

Gwen Black, PharmD (Vice-Chairperson)  
David Elwell, MD  
James Feinstein, MD (Chairperson)  
Kimberley Jackson, DO  
Emily Kosirog, PharmD  
Thuy McKittrick, PharmD  
Daralyn Morgenson, PharmD  
Lynn Parry, MD  
Davin Patel, PharmD  
Kelet Robinson, MD  
Marisa Wiktor, MD

#### B. Members Excused

No members excused

#### C. Staff Present

##### HCPF Pharmacy Office

Jim Leonard, PharmD  
Brittany Schock, PharmD



### Magellan RX Management

Jessica Czechowski, PharmD  
Diana Kastendieck, PharmD

### 3. Approval of Minutes

J. FEINSTEIN asked for approval of the minutes from the January 12<sup>th</sup>, 2021 meeting. L. PARRY made a motion to approve the minutes as they stand. G. BLACK seconded. The minutes were approved with no audible dissent.

### 4. Department Updates

B. SCHOCK reviewed updates from last meeting.

- Diabetes Management - Insulins
- Glucagon, Self-Administered
- Lipotropics
- Cardiovascular Agents
  - Alpha-Blockers
  - Beta-Blockers & Combinations
  - Calcium Channel Blockers
- Leukotriene Modifiers
- Multiple Sclerosis Agents
- Anti-Parkinson Agents - Dopa Decarboxylase Inhibitors and Combinations, MAO-Bs, Dopamine Agonists, Other)
- Antimigraine Agents - Calcitonin Gene-related Peptide (CGRP) Inhibitors
- Atypical Antipsychotics
- Sedative Hypnotics - Non-Benzodiazepine and Benzodiazepine
- Benzodiazepines, Non-Sedative Hypnotic and Anxiolytic Non-Benzo
- Anorectal, Hemorrhoidal and Related Topical Anesthetic Agents
- Ophthalmic Anti-Inflammatory Agents
- Ophthalmic Glaucoma Agents

#### **Mass review drug classes:**

- Statins & Statin Combinations
- Lithium Agents
- Neurocognitive Disorder Agents
- Topical Steroids - Low Potency, Medium Potency, High Potency, and Very High Potency
- Growth Hormones
- Bile Salts
- Immune Globulins
- Intranasal Rhinitis Agents
- Ophthalmic Allergy agents



## 5. NEW BUSINESS

- A. B. SCHOCK reviewed updates from the Prior Authorization Call Center.
- Prior Authorization Requests for Pharmacy Benefits can be faxed or called-in, in most cases.
  - First quarter 2021: 75% PARs approved, 21% denied and 4% change in therapy.
  - Average hold time for the call center for the past month was 52 seconds.
  - Average call length was 7 minutes and 16 seconds.
- B. J. FEINSTEIN discussed new topic regarding standardizing language around motions.
- Discussed streamlining language around motions, aspects of motions and terminology used.
  - Solicit committee's input about
    - Aspects of motions that are important to consider regarding safety and efficacy.
    - More consistent language for motions.
    - Committee will email B. SCHOCK directly with phrasing. Will assemble document to review at next meeting and use moving forward.

## 6. Rules

- J. FEINSTEIN presented rules for drug classes that are up for review and will contain public testimony, class updates and market share, and Committee discussion.
- Each review will contain:
    - Oral presentations by manufacturers, providers and public.
    - Overview for each Drug Class including market share and FDA updates.
    - Committee Discussion and Recommendations for each Class.
  - Mass review Drug classes will only include:
    - Overview for each Drug Class including market share and FDA updates.
  - Rules for presentation
    - Oral presentations are restricted to products that are being reviewed for PDL status.
    - Presentations will be limited to 3 minutes per representative per drug product.
    - Representatives will be called to present in the order in which they signed in by drug class.
    - Presentations will be limited by verbal comments.
    - No visual aids other than designated handouts are permitted.
    - Presentations should follow the one page summary that was submitted to



the Department.

- ❖ Stakeholders comments are to:
  - ◆ Be limited to clinical information only;
  - ◆ Exclude any reference to cost
  - ◆ Exclude anecdotal content
  - ◆ Exclude general drug or disease specific economic information
- The audience will be considered a reference tool for the Committee.
- The Committee will discuss topics and audience participation will be allowed if P&T members ask for clarification.
- The Department disseminated recently received public comments to the Committee members prior to the meeting.

J. FEINSTEIN presented Committee Discussion and Recommendations for each Class should address the following questions:

- Do the agents differ in efficacy or effectiveness?
- Do the agents differ in safety or adverse effects?
- Are there subgroups for which one agent is associated with either differences in efficacy or effectiveness, or differences in safety or adverse effects?

### Factual Inaccuracy:

J. FEINSTEIN presented Factual Inaccuracy. During a Committee meeting, if a stakeholder believes that a factual inaccuracy has been stated by a Committee member, the stakeholder may hand a note or email the Department representative. The stakeholder must provide the factual inaccuracy or a summary of the inaccuracy on the note. The Department representative will forward any comment to the Chair or Vice Chair. The Committee Chair/Vice Chair will then determine if there is a need to publicly hear the inaccuracy prior to moving forward with motions and discussion. The Chair/Vice Chair will state the purported factual inaccuracy and will ask the Committee if they want to hear testimony regarding the factual inaccuracy. When providing testimony, the stakeholder must provide evidence to support the claim of inaccuracy and cannot provide opinions on the drug class being considered.

## A. DRUG CLASSES FOR REVIEW

J. FEINSTEIN moved to discuss Drug Classes for Review. B. SCHOCK asked for any disclosures for all the classes to be reviewed. No disclosures noted. B. SCHOCK asked for all speakers to provide disclosures before speaking.

1. J. FEINSTEIN moved to discuss **Non-Opioid Analgesics**. No speakers. J. CZECHOWSKI reviewed utilization and updates. L. PARRY made a motion that at least two oral agents with different mechanisms of action be available. D. MORGENSON



seconded. The motion passed with no audible dissent. K. ROBINSON made a motion that at least one topical agent be preferred. L. PARRY seconded. The motion passed with no audible dissent. K. JACKSON made a motion that at least one oral agent that can be given via feeding tube be preferred. M. WIKTOR seconded. The motion passed with no audible dissent. L. PARRY a motion that at least one agent with pediatric indication be available. G. BLACK seconded. The motion passed with no audible dissent.

2. J. FEINSTEIN moved to discuss **Opioids, Short-Acting**. No speakers. J. CZECHOWSKI reviewed utilization and updates. G. BLACK made a motion that at least two single agents and two combination agents be preferred. D. PATEL seconded. The motion passed with no audible dissent. M. WIKTOR made a motion that at least one liquid short-acting formulation be available as a preferred agent. K. JACKSON seconded. The motion passed with no audible dissent. M. WIKTOR made a motion that at least one Schedule IV short-acting opioid be available as preferred. D. ELWELL seconded. The motion passed with 10 ayes and 1 abstaining. K. JACKSON made a motion that at least one non-oral short-acting opioid be available as preferred. J. FEINSTEIN seconded. The motion passed with no audible dissent.
3. J. FEINSTEIN moved to discuss **Fentanyl Preparations**. No speakers. J. CZECHOWSKI reviewed utilization and updates. No motions made by the committee.
4. J. FEINSTEIN moved to discuss **Opioids, Long-Acting**. No speakers. J. CZECHOWSKI reviewed utilization and updates. L. PARRY made a motion that at least one Schedule III or IV long-acting opioid be included as preferred. E. KOSIROG seconded. The motion passed with no audible dissent. K. JACKSON made a motion that one long-acting agent be available that can be given via feeding tube or for patients who have difficulty swallowing. K. ROBINSON seconded. The motion passed with no audible dissent. L. PARRY made a motion that at least one long-acting opioid agent be available in transdermal form. K. JACKSON seconded. The motion passed with no audible dissent.
5. J. FEINSTEIN moved to discuss **Angiotensin Modulators and Combinations, ACEIs and ACEI Combinations**. No speakers. J. CZECHOWSKI reviewed utilization and updates. K. ROBINSON made a motion that at least two ACEIs and two ACEI Combinations be preferred. G. BLACK seconded. The motion passed with no audible dissent. K. JACKSON made a motion that at least one product be available for members who cannot swallow whole or crushed tablets. L. PARRY seconded. The motion passed with no audible dissent. J. FEINSTEIN made a motion that at least one ACEI for pediatric indications be preferred. L. PARRY seconded. The motion passed with no audible dissent.
6. J. FEINSTEIN moved to discuss **Angiotensin Modulators and Combinations, ARBs**



**and ARB Combinations.** MELISSA SOMMERS from Novartis spoke on Entresto. J. CZECHOWSKI reviewed utilization and updates. L. PARRY made a motion that at least two ARBs and two ARB Combinations be preferred. K. ROBINSON seconded. The motion passed with no audible dissent. E. KOSIROG made a motion that at least one combination product be made available for members with heart failure with reduced ejection fraction. L. PARRY seconded. The motion passed with 10 ayes and 1 abstaining. J. FEINSTEIN made a motion that at least one ARB for pediatric indications be preferred. E. KOSIROG seconded. The motion passed with 10 ayes and 1 abstaining.

7. J. FEINSTEIN moved to discuss **Angiotensin Modulators and Combinations, Renin Inhibitor and Combinations.** No speakers. J. CZECHOWSKI reviewed utilization and updates. No motions made by the committee.
8. J. FEINSTEIN moved to discuss **Acne Products, Topical.** No speakers. J. CZECHOWSKI reviewed utilization and updates. J. FEINSTEIN made a motion that at least one product be available as preferred in each topical category (antibiotics, antibiotic combinations, retinoids, other). L. PARRY seconded. The motion passed with no audible dissent. G. BLACK made a motion that at least one agent be preferred that is recommended for the treatment of inflammatory acne. J. FEINSTEIN seconded. The motion passed with no audible dissent.
9. J. FEINSTEIN moved to discuss **Acne Products, Oral Isotretinoin.** No speakers. J. CZECHOWSKI reviewed utilization and updates. No motions made by the committee.

Break at 14:55 MT and reconvened at 15:05 MT.

10. G. BLACK moved to discuss **Antineoplastics, Topical.** No speakers. J. CZECHOWSKI reviewed utilization and updates. G. BLACK made a motion that at least one agent be preferred for the treatment of cutaneous T-cell lymphoma (CTCL). J. FEINSTEIN seconded. The motion passed with no audible dissent. L. PARRY made a motion that at least one agent be preferred for actinic keratosis. D. PATEL seconded. The motion passed with no audible dissent.
11. G. BLACK moved to discuss **Rosacea Agents.** No speakers. J. CZECHOWSKI reviewed utilization and updates. J. FEINSTEIN made a motion that preferred agents should include cream, gel, foam and lotion. L. PARRY seconded. The motion passed with no audible dissent. L. PARRY made a motion that one formulation be available for those individuals who are of child-bearing potential. E. KOSIROG seconded. The motion passed with no audible dissent.
12. G. BLACK moved to discuss **Phosphate Binders.** No speakers. J. CZECHOWSKI reviewed utilization and updates. L. PARRY made a motion that at least one agent



with and without calcium be available. E. KOSIROG seconded. The motion passed with no audible dissent. L. PARRY made a motion that at least one agent be preferred with a pediatric indication. J. FEINSTEIN seconded. The motion passed with no audible dissent. K. ROBINSON made a motion that at least one agent with and without calcium that can be administered with a feeding tube be available. K. JACKSON seconded. The motion passed with no audible dissent.

- 13.G. BLACK moved to discuss **Respiratory Inhalants - Inhaled Anticholinergics and Combinations**. No speakers. J. CZECHOWSKI reviewed utilization and updates. J. FEINSTEIN made a motion that at least one agent from each subclass with a pediatric indication be preferred. L. PARRY seconded. The motion passed with no audible dissent. E. KOSIROG made a motion that at least one product and one combination product from each subclass be preferred. L. PARRY seconded. The motion passed with no audible dissent.
- 14.G. BLACK moved to discuss **Respiratory Inhalants - Inhaled Beta<sub>2</sub> Agonists (short and long-acting)**. JENNIFER SHEAR from Teva spoke on ProAir Digihaler, AirDuo and ArmonAir Digihaler. BRIDGET RALEIGH, nurse practitioner at Children's Hospital Colorado spoke on Respiratory Inhalants. J. CZECHOWSKI reviewed utilization and updates. E. KOSIROG made a motion that at least one MDI be available as preferred. L. PARRY seconded. The motion passed with no audible dissent. G. BLACK made a motion that at least one short-acting inhaled solution be available as preferred. J. FEINSTEIN seconded. The motion passed with no audible dissent.
- 15.G. BLACK moved to discuss **Respiratory Inhalants - Inhaled Corticosteroids and Combinations**. JOEL CAVALLO with AMAG/COVIS spoke on Alvesco. J. CZECHOWSKI reviewed utilization and updates. L. PARRY made a motion at least one single agent product from each dose form (MDI, DPI, breath-activated and nebule) be preferred. J. FEINSTEIN seconded. The motion passed with no audible dissent. L. PARRY made a motion at least one combination product from each dosage form (MDI, DPI) be preferred. J. FEINSTEIN seconded. The motion passed with no audible dissent. K. ROBINSON made a motion at least one low-dose combination ICS product with pediatric indications be available in each dosage form. L. PARRY seconded. The motion passed with no audible dissent. E. KOSIROG made a motion that at least one combination agent be preferred that is guideline recommended for PRN and scheduled use. T. MCKITRICK seconded. The motion passed with no audible dissent.
- 16.G. BLACK moved to discuss **Respiratory Inhalants - Phosphodiesterase Inhibitors (PDEIs)**. No speakers. J. CZECHOWSKI reviewed utilization and updates. No motions made by the committee.
- 17.J. FEINSTEIN moved to discuss **Mass Review Categories**.
- Tetracyclines



- No past motions
- Skeletal Muscle Relaxants
  - Motions:
    - Include at least one agent to treat spasticity as preferred.
    - Include at least one skeletal muscle relaxant as preferred.
    - Soma has a high addiction profile and should not be preferred because of safety reasons.
- Topical Immunomodulators
  - No past motions.
- Androgenic Agents
  - Motions:
    - At least one product be available as topical and injectable.
    - At least one patch and gel formulation be available.
- Antihistamines (Newer Generation and Combinations)
  - Motions:
    - At least one formulation be available for those that can't swallow pills.
    - To make available at least two different antihistamine agents.
- Benign Prostatic Hypertrophy (BPH) Agents
  - Motions:
    - At least one agent from each of the 4 categories (alpha blocker, 5-alpha reductase inhibitors, combinations, PDE Inhibitors) be preferred.
    - Consideration be given for at least two alpha-blockers, one that is uro-selective and one that is non-uro-selective be preferred.
    - An agent that can be given through a feeding tube be preferred.

L. PARRY made a motion to approve the mass review classes with current motions from last year's meeting. K. JACKSON seconded. The motion passed with no audible dissent. L. PARRY made a motion to adjourn meeting. M. WIKTOR seconded. The motion passed with no audible dissent.

B. SCHOCK announced the next meeting for July 13<sup>th</sup>, 2021.

J. FEINSTEIN adjourned the meeting at 16:09 MT.

By: \_\_\_\_\_  
James Feinstein, MD

Date: \_\_\_\_\_





Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Committee Coordinator at 303- 866-6371 or [brittany.schock@state.co.us](mailto:brittany.schock@state.co.us) or the 504/ADA Coordinator [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting.

